The Global Hypertension Report by the World Health Organization (WHO) revealed that 1.4 billion people were living with ...

Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired ...

Blood pressure medications work in different ways to bring blood pressure to within an optimal range. Read on for more.

High blood pressure, clinically known as hypertension, affects nearly half of U.S. adults and remains a leading risk factor for heart disease, stroke and kidney disease. Often called the " ...

Ralinepag works by restoring prostacyclin signaling and activating prostacyclin receptors to affect pathways that play a role in the progression of PAH. The drug was originally formulated as an ...

A study led by investigators from Johns Hopkins Medicine found that some patients with discoid lupus erythematosus - a form ...

Researchers explored the relationship between NSAID use and incident hypertension among younger patients with axial spondyloarthritis.

AstraZeneca’s baxdrostat (Baxfendy) has secured FDA approval for the treatment of hypertension in combination with other antihypertensives. Baxdrostat is the first aldosterone synthase inhibitor, ...

AstraZeneca AZN announced that the FDA has approved baxdrostat for treating adult patients with uncontrolled or treatment-resistant hypertension as an add-on to other antihypertensive drugs.

After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI) baxdrostat has continued to pay off. The FDA has given the all-clear to ...

AstraZeneca AZN-0.64%decrease; red down pointing triangle said it received U.S. approval for a new hypertension treatment, getting the green light to launch a drug the U.K. pharmaceutical company ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in ...